A new study supports the prognostic value of the PCA3 prostate cancer marker

    Ticker Symbol: CUR

    QUEBEC CITY, Oct. 9 /CNW Telbec/ - DiagnoCure Inc. (TSX: CUR), a life
sciences company commercializing high-value cancer diagnostic tests and
delivering laboratory services, reported today that PCA3, the Company's highly
specific prostate cancer marker, is featured in an important article in the
November issue of the Journal of Urology. The new published study supports the
use of a PCA3-based test as a tool for better assessing the prognosis of
prostate cancer.

    PCA3 shows prognostic value

    The Journal of Urology article (180: 1975-1979, 2008) reports on a study
of 72 men with prostate cancer from whom post digital rectal examination urine
specimens were collected, before radical prostatectomy, and tested for both
PCA3 and serum PSA. The PCA3 score was shown to be a better indicator for
prostate cancer stage than PSA because it more accurately predicted the spread
of prostate cancer beyond the prostate capsule. The study also established a
correlation between the tumor volume and the PCA3 score, which could represent
an excellent marker for following patients on active surveillance.
    "We are pleased that more peer-reviewed scientific publications continue
to confirm PCA3's clinical value. There are many clinical questions about a
patient's cancer that require reliable answers to make appropriate treatment
and surveillance decisions. PCA3 is currently used to better predict biopsy
outcome, but with additional studies such as this one, PCA3 is promising to be
even more clinically useful for prostate cancer patients", stated John
Schafer, President and CEO of DiagnoCure.
    The PCA3 test is now available across the European Union and from five
laboratories in the United-States that offer a PCA3-based test using analyst
specific reagents (ASR) manufactured by Gen-Probe. The test is also available
at two clinical laboratories in Canada.

    About DiagnoCure

    DiagnoCure (TSX: CUR) is a life sciences company commercializing
high-value cancer diagnostic tests and delivering laboratory services that
increase clinician and patient confidence in making critical treatment
decisions. DiagnoCure Oncology Laboratories, a subsidiary of DiagnoCure Inc.,
recently launched the Previstage(TM) GCC Colorectal Cancer Staging Test, the
first GCC-based molecular test for the management of colorectal cancer. The
Company also has a strategic alliance with Gen-Probe (NASDAQ:   GPRO) for the
development and commercialization of a second-generation prostate cancer test
using PCA3, DiagnoCure's proprietary molecular marker. This test is also
available through laboratories in the U.S. using PCA3 analyte specific
reagents (ASR) from Gen-Probe, in Europe as the CE-marked PROGENSA(TM) PCA3 in
vitro assay, and in Canada. In addition to its own research, the Company
intends to acquire or in-license additional promising cancer biomarkers from
both academic and commercial institutions. For more information, visit

    Forward-looking statements

    This release contains forward-looking statements that involve known and
unknown risks, uncertainties and assumptions that may cause actual results to
differ materially from those expected. By their very nature, forward-looking
statements are based on expectations and hypotheses and also involve risks and
uncertainties, known and unknown, many of which are beyond DiagnoCure's
control. As a result, investors are cautioned not to place undue reliance on
these forward-looking statements. The forward-looking statements regarding the
outcome of research and development projects, clinical studies and future
revenues are based on management expectations. In addition, the reader is
referred to the applicable general risks and uncertainties described in
DiagnoCure's most recent Annual Information Form under the heading "Risk
Factors". DiagnoCure undertakes no obligation to publicly update or revise any
forward-looking statements contained herein.
    %SEDAR: 00003671EF

For further information:

For further information: Investors: DiagnoCure Inc.: J.F. Bureau, CFA,
Sr. Vice President and CFO, (418) 527-6100, communications@diagnocure.com;
Media: U.S.: Troy Pearson, Mentus Life Science, (858) 455-5500 X320,
Troy@mentus.com; Canada: Jean-Pierre Trudel, Jean-Pierre Trudel & Associates,
(514) 347-6111, jp.trudel@videotron.ca

Organization Profile

DiagnoCure Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890